Subsequently, two phase III, randomized, double-blind, placebo-controlled, multicenter studies demonstrated that the combination of plerixafor plus G-CSF was well tolerated, and mobilized significantly higher numbers of stem cells than G-CSF alone in patients with NHL or multiple myeloma [12, 13]. The gene discussed is CSF3; the disease is non-Hodgkin lymphoma.